DK2254590T3 - Fremgangsmåder og præparater til oral administration af insulin - Google Patents

Fremgangsmåder og præparater til oral administration af insulin

Info

Publication number
DK2254590T3
DK2254590T3 DK09700655.5T DK09700655T DK2254590T3 DK 2254590 T3 DK2254590 T3 DK 2254590T3 DK 09700655 T DK09700655 T DK 09700655T DK 2254590 T3 DK2254590 T3 DK 2254590T3
Authority
DK
Denmark
Prior art keywords
insulin
preparations
methods
oral administration
oral
Prior art date
Application number
DK09700655.5T
Other languages
English (en)
Inventor
Alexander Vol
Orna Gribova
Original Assignee
Oshadi Drug Administration Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd
Application granted granted Critical
Publication of DK2254590T3 publication Critical patent/DK2254590T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK09700655.5T 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administration af insulin DK2254590T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8029508P 2008-07-14 2008-07-14
US10202008P 2008-10-02 2008-10-02
PCT/IL2009/000037 WO2009087634A2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin

Publications (1)

Publication Number Publication Date
DK2254590T3 true DK2254590T3 (da) 2013-01-28

Family

ID=40326402

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09700655.5T DK2254590T3 (da) 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administration af insulin
DK09701269.4T DK2231123T3 (da) 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administrationaf protein- og peptidterapimidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09701269.4T DK2231123T3 (da) 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administrationaf protein- og peptidterapimidler

Country Status (16)

Country Link
US (3) US20100278922A1 (da)
EP (2) EP2231123B1 (da)
JP (1) JP5432183B2 (da)
KR (1) KR101588066B1 (da)
AU (2) AU2009203530B2 (da)
BR (1) BRPI0906866A2 (da)
CA (2) CA2711554C (da)
DK (2) DK2254590T3 (da)
EA (1) EA018461B1 (da)
ES (2) ES2398015T3 (da)
HK (1) HK1148945A1 (da)
IL (3) IL188647A0 (da)
MX (1) MX2010007462A (da)
NZ (1) NZ586374A (da)
WO (2) WO2009087634A2 (da)
ZA (1) ZA201004480B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IN2012DN00311A (da) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
TWI723339B (zh) * 2011-05-02 2021-04-01 美商千禧製藥公司 抗-α4β7抗體之調配物
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
US20150366946A1 (en) * 2013-01-29 2015-12-24 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes
ES2502691B1 (es) * 2013-09-25 2015-07-07 Sani-Red, S.L. Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
WO2015066717A1 (en) * 2013-11-04 2015-05-07 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
KR102418550B1 (ko) * 2015-11-03 2022-07-06 삼성전자주식회사 포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법
WO2017141262A1 (en) * 2016-02-19 2017-08-24 Indian Institute Of Technology, Bombay Orally administrable pharmaceutical preparation containing protein
EP3456859A1 (en) 2017-09-13 2019-03-20 Rolex Sa Protective coating for a complex watch component
CN109819650A (zh) * 2017-09-25 2019-05-28 春布里泽·格奥尔基·格奥尔基耶维奇 具有抗病毒和抗细菌活性的热稳定组合物及其用途
IT201800007947A1 (it) 2018-08-07 2020-02-07 Vetagro Int Srl Metodo per preparare una composizione di aminoacidi per consentire la corrispondenza dei singoli fabbisogni di amminoacidi ad un soggetto in base all'età, al genere, all'attività fisica e alla genetica
CA3134550A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
KR20220114618A (ko) 2019-12-17 2022-08-17 9286-3620 퀘벡 인크. 단백질/폴리사카라이드 코아세르베이트의 인시츄 형성에 기반한 경구 전달 시스템
TW202136318A (zh) 2020-01-28 2021-10-01 美商建南德克公司 用於治療癌症的 IL15/IL15R α 異二聚體 Fc 融合蛋白質
CN116194102A (zh) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 用于治疗急性疼痛和降低胃灼热的严重程度和/或风险的包含布洛芬和法莫替丁的单位口服剂量组合物
WO2023286049A1 (en) 2021-07-12 2023-01-19 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers
US20230399362A1 (en) 2022-06-13 2023-12-14 B.A.I. Laboratories, Llc Interleukin-13 binding cyclic oligopeptides and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) * 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2767718B1 (fr) * 1997-08-28 1999-10-22 Oreal Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
WO1999012640A1 (en) * 1997-09-09 1999-03-18 Select Release, L.C. Coated particles, methods of making and using
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) * 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja) * 2000-01-28 2011-02-16 Ｊｓｒ株式会社 疎水化コロイダルシリカの製造方法
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
JP2004521857A (ja) * 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
DE50012404D1 (de) 2000-08-11 2006-05-11 Lohmann Animal Health Gmbh W/o Emulsion Adjuvanszuzammensetzungen für Impstoffen
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) * 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
CA2465779A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
WO2003059288A2 (en) * 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
DE60314495T2 (de) 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
US7244498B2 (en) * 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
CA2511530C (en) * 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CA2541445A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US7288134B2 (en) * 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
EP1922367B1 (en) * 2005-08-09 2016-03-30 University of Sunderland Fingerprint detection using hydrophobic silica particles and methods of making same
ES2761937T3 (es) * 2005-10-24 2020-05-21 Magsense Life Sciences Inc Método para preparar micropartículas recubiertas con polímero
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
US20070184076A1 (en) * 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IN2012DN00311A (da) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd

Also Published As

Publication number Publication date
KR20100119541A (ko) 2010-11-09
ES2398015T3 (es) 2013-03-13
EP2254590A4 (en) 2012-01-25
US20150147399A1 (en) 2015-05-28
JP5432183B2 (ja) 2014-03-05
US8936786B2 (en) 2015-01-20
EA201070827A1 (ru) 2010-12-30
EP2254590A2 (en) 2010-12-01
IL188647A0 (en) 2008-11-03
IL206834A (en) 2015-09-24
EP2231123A4 (en) 2011-09-07
WO2009087634A2 (en) 2009-07-16
IL206835A0 (en) 2010-12-30
CA2711556A1 (en) 2009-07-16
EA018461B1 (ru) 2013-08-30
US20100278922A1 (en) 2010-11-04
KR101588066B1 (ko) 2016-01-22
IL206835A (en) 2017-09-28
EP2254590B1 (en) 2012-10-10
JP2011509287A (ja) 2011-03-24
CA2711554C (en) 2017-01-03
AU2009203530B2 (en) 2013-10-24
DK2231123T3 (da) 2013-02-04
WO2009087633A2 (en) 2009-07-16
BRPI0906866A2 (pt) 2019-02-26
IL206834A0 (en) 2010-12-30
CA2711554A1 (en) 2009-07-16
AU2009203529A1 (en) 2009-07-16
EP2231123A2 (en) 2010-09-29
ES2397061T3 (es) 2013-03-04
US9949924B2 (en) 2018-04-24
WO2009087634A3 (en) 2010-01-07
HK1148945A1 (en) 2011-09-23
NZ586374A (en) 2011-10-28
ZA201004480B (en) 2011-09-28
AU2009203530A1 (en) 2009-07-16
EP2231123B1 (en) 2012-10-24
MX2010007462A (es) 2010-08-23
US20100297245A1 (en) 2010-11-25
WO2009087633A3 (en) 2010-03-11
AU2009203529B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
DK2254590T3 (da) Fremgangsmåder og præparater til oral administration af insulin
DK2275086T3 (da) Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
HK1249031A1 (zh) 疫苗施用的方法
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3011975T3 (da) Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
DK3045043T3 (da) Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2493474T3 (da) Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
DK2320911T3 (da) Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK2114531T3 (da) Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2358669T3 (da) Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf
DK2413912T3 (da) Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
DK2413913T3 (da) Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
DK2244783T3 (da) Flygtige anæstetiske sammensætninger og fremgangsmåder til anvendelse
DK2320740T3 (da) Farmaceutiske sammensætninger af clevidipin og fremgangsmåder tilfremstilling af koncentrationer deraf med lave urenhedsgrader
DK2413899T3 (da) Dentalt anæstetikum omfattende tetracain og en vasokonstriktor til intranasal indgivelse
DK2068885T3 (da) D-vitaminpræparater og fremgangsmåde til administration til et menneske
DK2307445T3 (da) Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2172207T3 (da) Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
DK2158194T3 (da) Derivater af 7-alkynyl-1,8-naphtyridoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf